Lucid Diagnostics (NASDAQ:LUCD) Director Dennis Matheis Buys 245,000 Shares

Lucid Diagnostics Inc. (NASDAQ:LUCD) Director Dennis Matheis purchased 245,000 shares of Lucid Diagnostics stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $1.00 per share, for a total transaction of $245,000.00. Following the acquisition, the director owned 1,033,443 shares in the company, valued at approximately $1,033,443. This trade represents a 31.07% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD remained flat at $1.00 during trading on Thursday. The stock had a trading volume of 938,377 shares, compared to its average volume of 1,150,097. Lucid Diagnostics Inc. has a fifty-two week low of $0.90 and a fifty-two week high of $1.70. The company’s 50-day moving average is $1.17 and its two-hundred day moving average is $1.18. The stock has a market cap of $203.07 million, a price-to-earnings ratio of -2.13 and a beta of 1.10.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.38 million. On average, analysts anticipate that Lucid Diagnostics Inc. will post -0.22 EPS for the current year.

Analyst Upgrades and Downgrades

LUCD has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. BTIG Research restated a “buy” rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a report on Friday, May 15th. Maxim Group reduced their price objective on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Wall Street Zen lowered shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $4.13.

Hedge Funds Weigh In On Lucid Diagnostics

Institutional investors have recently bought and sold shares of the company. Perkins Capital Management Inc. acquired a new position in Lucid Diagnostics in the 3rd quarter valued at about $1,138,000. Ghisallo Capital Management LLC acquired a new position in Lucid Diagnostics in the 3rd quarter valued at about $2,990,000. Aberdeen Group plc acquired a new position in Lucid Diagnostics in the 3rd quarter valued at about $2,525,000. Sunbelt Securities Inc. grew its position in Lucid Diagnostics by 134.4% in the 1st quarter. Sunbelt Securities Inc. now owns 900,013 shares of the company’s stock valued at $1,035,000 after acquiring an additional 516,014 shares in the last quarter. Finally, XML Financial LLC grew its position in Lucid Diagnostics by 24.8% in the 1st quarter. XML Financial LLC now owns 223,195 shares of the company’s stock valued at $257,000 after acquiring an additional 44,400 shares in the last quarter. 74.01% of the stock is owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.